Kornimate/medical-research-clean huggingface dataset:
technetium based radioguided surgery for prostate cancer (trace) study

Conditions: Prostate Cancer

Summary: psma-radioguided surgery

given the difficulty visualizing lymph node involvement with pre-operative imaging alone, and the potential to miss metastatic nodal involvement on template plnd, radioguided surgery has been proposed as a technique to improve intra-operative detection and clearance. 99mtechnetium (99mtc) is a frequently used radioisotope in nuclear medicine, with favourable radiation properties and commercial availability\[11\]. it has a 6-hour half-life, and is suited to allow target tissue accumulation, while minimizing patients and investigator radiation exposure. novel molecule-targeted radiopharmaceuticals using 99mtc and other radioisotopes in the setting of pc have increasing potential for diagnostic imaging, monitoring of therapeutic interventions and directed surgery\[11, 12\]. in relation to radioguided surgery, 99mtc -based psma-radioguided surgery (99mtc-psma-rgs) was deployed in a feasibility study. using a specifically designed 99mtc based tracer, 99mtc-mas3-y-nal-k(sub-kue), or in short tc-99m-psma i\&s, combined with a gamma probe, guidance of the surgical resection of recurrent pc lymph node metastases was undertaken in 132 patients, yielding a sensitivity of 84% and specificity of 100% and detecting metastases as small as 3mm\[15, 16\]. this raises the question as to whether a combination of psma pet/ct imaging and psma-radioguided surgery may increase the cure rate in patients undergoing operative management of pc, by increasing detection sensitivity and specificity of nodal metastases.

Eligibility criteria:
inclusion criteria: * male, aged ≥ 18 years. * hormone-sensitive recurrent prostate cancer after radical prostatectomy * \<3 soft tissue lesions (lymph node; connective tissue) within the pelvis or retroperitoneum with sufficient psma expression (≥3 times regional vascular activity level) as determined by psma-based pet * psa-value \<4ng/ml * had a psma pet/ct within 60 days before surgery * suitable for salvage lymph node dissection, as per institutional guidelines. * who performance status 0,1, or 2. * written informed consent. exclusion criteria: * suspicion of local recurrent prostate cancer within the prostatic fossa not treatable by surgery * nonregional lymphadenopathy (cm1a) or distant metastases (cm1b/c) as assessed by preoperative psma pet/ct. * ongoing androgen deprivation therapy (adt) or within 6 months prior to surgery. * severe claustrophobia interfering with pet/ct or spect/ct scanning.
portal hypertension and liver resection in patients with hepatocellular carcinoma

Conditions: Primary Liver Cancers

Summary: according to the bclc guidelines, surgical resection of hepatocellular carcinoma complicating cirrhosis is restricted to patients with preserved liver function, single nodule without vascular invasion and with hepatic venous gradient below 10 mmhg. however, other guideline treatment, especially from eastern countries demonstrated that surgical resection is safe and feasible and provides better survival than the treatment recommended by the bclc system for patients with similar stage. the primary goal of this study is to assess the impact of hvpg on short and long-term outcomes in hcc patients who undergo liver resection.

patients with hcc and candidates for hepatectomy are classified into two groups according to the presence of portal hypertension. short- and long-term outcomes will be compared.

Eligibility criteria:
patients with hepatocellular carcinoma who undergo surgical resection (intention to treat analysis)

Keywords: portal hypertension, hepatocellular carcinoma, resection
neoadjuvant chemotherapy in epithelial ovarian cancer

Conditions: Ovarian Cancer; Fallopian Tube Carcinoma; Peritoneal Carcinoma

Summary: the purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.


Eligibility criteria:
inclusion criteria: * female patients ≥18 years. * karnofsky performance scale ≥ 60% * histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with the exception of mucinous, clear cell, low-grade carcinoma and carcinosarcoma histologies. * documented international federation of gynecologic oncology (figo) stage iiic-iv oligometastatic unsuitable for complete primary cytoreductive surgery. inoperability must be confirmed by open laparoscopy or by laparotomy. * adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery: * white blood cells \>3,000/µl, absolute neutrophil count ≥1,500/µl, platelets ≥100,000/µl, hemoglobin ≥9 g/dl, * serum creatinine \<1.25 x upper normal limit (unl) or creatinine clearance ≥60 ml/min according to cockroft-gault formula or to local lab measurement * serum bilirubin \<1.25 x unl, ast(sgot) and alt(sgpt) \<2.5 x unl. * signed informed consent obtained prior to any study-specific procedures exclusion criteria: * mucinous, clear cell, low-grade carcinoma and carcinosarcoma histologies. * synchronous or previous other malignancies within 3 years prior to starting study treatment, with the exception of adequately treated non-melanomatous skin cancer or carcinoma in situ (of the cervix or breast or other sites). * patients with brain metastases, seizure not controlled with standard medical therapy, or history of cerebrovascular accident (cva, stroke) or transient ischemic attack (tia) or subarachnoid hemorrhage within 6 months from the enrollment on this study. * any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol (including but not limited to impaired cardiac function or clinically significant cardiac diseases, active or uncontrolled infections, hiv-positive patients on antiretroviral therapy, uncontrolled diabetes, cirrhosis, chronic active or persistent hepatitis, impaired respiratory function requiring oxygen-dependence,serious psychiatric disorders). * pregnant or breastfeeding women.

Keywords: neoadjuvant chemotherapy ovarian cancer fallopian tube carcinoma peritoneal carcinoma randomized study
feasibility of radiotherapy and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma

Conditions: Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma

Summary: the aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma


Eligibility criteria:
inclusion criteria: * histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease * who performance status of 0 or 1 * complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed * maximum delay after surgery: 8 weeks * no previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ * adequate bon marrow reserve * no previous chemotherapy or radiotherapy * expected survival \> 6 months exclusion criteria: * active infection * metastatic disease * inadequate liver function after derivative surgery * inadequate renal function * pregnancy, breast feeding * use of any other investigational agent in the month before enrollment * patients with grade 2 or more neuropathy
leiden university medical center mini donor bank

Conditions: Malaria; Schistosoma Mansoni; Schistosoma Haematobium; Diabetes; Asthma

Summary: (bio)medical research, particularly immunological, metabolic, transcriptional or biological assays, occasionally require the use of fresh blood (peripheral mononuclear cells) or urine. in order to comply with international guidelines for good clinical practice, the investigators propose to establish a mini donor bank to be able to obtain fresh blood or urine from voluntary donors. recruitment of volunteers will be a continuous process. volunteers will consent to occasional blood- or urine donation.


Eligibility criteria:
inclusion criteria: 1. subject is aged ≥ 18 and ≤ 65 years and in good health. 2. subject has adequate understanding of the procedures of the study. 3. subject is able to communicate well with the investigator. 4. subject has signed informed consent. 5. subject refrains from donation to the sanquin blood bank. exclusion criteria: 1. previous vasovagal collapse during venepuncture. 2. for female participants: pregnancy or lactation. 3. presence of any chronic systemic condition, which could compromise the health of the volunteer when performing venepuncture or interfere with the interpretation of immunological or metabolic test results. 4. chronic use of immunosuppressive drugs. 5. total blood volume donated exceeding \>500 ml in the past 4 months.
magnesium sulfate and trigger points

Conditions: Myofascial Pain Syndrome

Summary: the patients will be randomly assigned to one of the two groups according to the treatment method: group i (masseter group) and group ii (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (trps) of magnesium sulphate according to the treatment group by the same operator. the treatment method for trps will be the primary predictor variable. patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. the participated patients will be assessed using pain score measured on a 10-point visual analogue scale (vas), the 0 indicating no pain and 10 indicating the worst pain ever


Eligibility criteria:
inclusion criteria: * definite diagnosis of myofascial pain * presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle; * no history of any invasive procedures of the related masseter muscle. exclusion criteria: * any painful conditions (other than myofascial trigger points) affecting the orofacial region * any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy); * pregnancy and lactation
headstart: evaluating the effectiveness of community art delivery for people newly diagnosed with hiv

Conditions: HIV Infections; Hiv

Summary: this is a cluster randomized controlled trial at 12 health centers in refugee settlements in uganda aiming to evaluate effectiveness of expansion of community antiretroviral therapy (art) delivery to people newly diagnosed with hiv in achieving hiv viral suppression.

community antiretroviral therapy (art) delivery is a differentiated care model that fosters social support and reduces time and transportation barriers yielding improved engagement in hiv care. in uganda, to participate in community art delivery, clients must be "stable" in care (\> 1 year on art and viral load \< 1,000 copies/ml). therefore, persons newly diagnosed with hiv are not eligible for community art delivery. community art delivery may benefit persons newly diagnosed with hiv in refugee settlements by bolstering social support and by bringing art closer to individuals living in these expansive rural settlements. the primary objective of this research is to evaluate the effectiveness of expanding community art delivery to clients newly diagnosed with hiv.

Eligibility criteria:
inclusion criteria: 1. evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. 2. subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. adult ≥18 years of age or mature minors or emancipated minor. mature minors are defined as individuals 14-17 years of age who have drug or alcohol dependency or a sexually transmitted infection. emancipated minors are defined as individuals below the age of majority (18 years) who are pregnant, married, have a child, or are self-sufficient. 4. tested hiv positive in the past 6 months and not already known to be hiv positive. 5. able to communicate in one of the following 5 study languages: kiswahili, runyankore, kinyarwanda, somali, or english. inclusion criteria for data abstraction only: 1. adult ≥18 years of age or mature minors or emancipated minor. 2. tested hiv positive in the past 6 months and not already known to be hiv positive. exclusion criteria: 1. pregnant and breastfeeding women. 2. clients deemed by the clinician(s) unfit for community-based care secondary to medical need. 3. concurrently enrolled in another biomedical clinical trial.

Keywords: community art delivery hiv antiretroviral therapy uganda refugee humanitarian
effects of dexmedetomidine used in continuous thoracic paravertebral blocks

Conditions: Post-thoracotomy Pain Syndrome

Summary: the purpose of this study is to explore the effectiveness of dexmedetomidine as an adjunctive analgesic, used in ultrasound-guided continuous thoracic paravertebral blocks for post-thoracotomy pain syndrome(ptps).

thoracic surgical procedures are among the most painful operations, and their outcomes are affected adversely by postoperative discomfort. post-thoracotomy pain syndrome (ptps) is a well-recognized complication of thoracotomy. post-thoracotomy pain control improves patient satisfaction and decreases postoperative complication morbidity. epidural analgesia used to be considered as the best method of pain relief after major surgery despite its side-effects, which includes hypotension, respiratory depression, incomplete or failed block, etc. recently, paravertebral block is an alternative technique that may offer a comparable analgesic effect and a better side-effect profile for post-thoracotomy pain. dexmedetomidine(dex) is a food and drug administration-approved, parenteral, selective α2-agonist that induces anxiolytic and analgesia without respiratory depression. it could provide dose-dependent sedation , analgesia , anti-anxiety and inhibition of sympathetic nerves and other effects . current studies with regard to the effectiveness of dex as an adjunctive medicine, used in ultrasound-guided continuous thoracic paravertebral blocks for ptps. the mechanical withdrawal threshold and vas scores are recorded. the consumption of opioid and general anesthetics during perioperative period are also recorded. to compare the incidence rates of side effects, such as nausea, vomiting, dizziness, hypotension and bradyarrhythmia in the first 3 days after operation among the groups.also,to measure and compare the level of inflammatory factor in different group.a questionnaire is adopted to investigate whether there are chronic pain symptoms happen at 6 months after the operation which aim to ptps.

Eligibility criteria:
inclusion criteria: 1. asa ⅰ～ⅲ patient undergoing thoracotomy; 2. written informed consent from the patient or the relatives of the participating patient. 3. bmi:18～25kg/m2 exclusion criteria: 1. mental illness; 2. epidural anesthesia or thoracic paravertebral blocks contraindicated; 3. people who have slow-type arrhythmias or hypotension; 4. people who have lung infection or sleep apnea syndrome; 5. people who have chronic renal failure; 6. alcohol or drug abuse; 7. already taking gabapentin, pregabalin, benzodiazepin or antidepression drug; 8. local anesthetics allergy;

Keywords: paravertebral blocks dexmedetomidine analgesia inflammatory response thoracotomy
ozone autohemotherapy for ischemic stroke sleep disorder

Conditions: Post-ischemic Stroke Insomnia

Summary: the purpose of this study is to observe the efficacy and safety of ozonated autohemotherapy in patients of post-ischemic stroke insomnia and to explore its mechanism of action.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for ischemic stroke; insomnia quality index (isi) score \> 7 points exclusion criteria: * acute ischemic stroke; associated with failure of important organs or malignant tumor; patients with worsening condition, new cerebral infarction or secondary cerebral hemorrhage; with comprehension or cognitive impairment, unable to fully understand the scale and unable to cooperate with treatment

Keywords: ischemic stroke insomnia ozone autohemotherapy
bioavailability and food effect study of tki258 (csf capsule vs. fmi tablet) in adult patients with advanced solid tumors

Conditions: Neoplasm; Cancer; Tumors

Summary: this study will evaluate the relative bioavailability of 2 oral formulations of tki258, and the effect of food on the bioavailability of tki258, in adult patients with advanced solid tumor.


Eligibility criteria:
inclusion criteria: * patients with an advanced solid tumor which has progressed despite standard therapy, or for which no standard therapy exists * world health organization (who) performance status ≤ 2 * patient must meet protocol-specified laboratory values exclusion criteria: * patients with brain cancer * patients who have concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study * patients who have not recovered from previous anti-cancer therapies * female patients who are pregnant, breast feeding, or not willing to use an effective method of birth control other protocol-defined inclusion/exclusion criteria may apply

Keywords: neoplasms cancer tumors administration, oral capsules chir258, chir-258, chir 258, tki258, tki-258, tki 258, bioavailability, food
a clinical trial to evaluate efficacy and safety of xeomin® injections for preventing chronic migraine

Conditions: Chronic Migraine

Summary: in this clinical trial, participants with chronic migraine will receive injections with xeomin or placebo into muscles of the head and neck. the purpose is to measure the change in monthly migraine days with xeomin injections compared to placebo injections. trial details include: * trial duration: 52 to 55 weeks; * screening period: 4 to 5 weeks; * treatment duration: 4 treatments, each about 12 weeks apart; and * visit frequency: about every 4 weeks, 14 visits in total. the first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of cm with or without aura according to the international classification of headache disorders edition 3 criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches; * participant age \< 50 years at the time of migraine onset; * participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≥ 15 headache days per month and history of ≥ 8 migraine days per month; and * during the last 28 days of the screening period, participant experiencing: ≥ 15 headache days and ≥ 8 migraine days that qualify as such per the headache diary. exclusion criteria: * diagnosis of other primary headache types, except tension-type headache, which is permitted; * diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction; * diagnosis of secondary headache types, except medication overuse headache, which is permitted; * currently taking \> 1 prescribed drug for the preventive treatment of migraine; * discontinuation of anti-calcitonin gene-related peptide (cgrp) / anti-cgrp receptor monoclonal antibody treatment less than 5 months prior to screening.
comparison of onsd and rso2 measurements between general and spinal anesthesia in c-section

Conditions: Intracranial Pressure Increase

Summary: general anesthesia and regional anesthesia can be chosen in cesarean operations. endotracheal intubation and mechanical ventilation are components of general anesthesia. endotracheal intubation has been shown to cause increased intracranial pressure. there is not enough information about the effect of spinal anesthesia on intracranial pressure during cesarean operations. increased intracranial pressure can cause neurological complications by disrupting brain perfusion. for this reason, the investigators think that the safe anesthesia method should be determined especially in pregnant patients who are at risk of increased intracranial pressure.


Eligibility criteria:
inclusion criteria: * undergoing elective c-section operation * age between 18-49 * asa i-ii * gestational week ≥ 36 exclusion criteria: * ophthalmologic disease and optic nerve pathology * increased intracranial pressure * history of cerebrovascular disease * cases where spinal anesthesia is contraindicated * emergency cesarean category level 1

Keywords: optic nerve sheath diameter intracranial pressure intraabdominal pressure cerebral regional oxygen saturation c-section
pulmonary hypertension on prognosis of acute myocardial infarction patients with reduced left ventricular function

Conditions: Acute Myocardial Infarction; Pulmonary Hypertension

Summary: pulmonary hypertension (ph) has a negative effect on acute myocardial infarction (ami) patients and appears to be closely associated with reduced left ventricular function. however, its impact on ami patients with reduced left ventricular function remains unclear. this retrospective study included ami patients with reduced left ventricular function to investigate the prognostic value of ph in this specific type of patient. meanwhile, a nomogram would be established basing on the identified independent risk factors, hoping to provide a novel risk stratification for them.


Eligibility criteria:
inclusion criteria: * the patients who were hospitalized for ami with reduced left ventricular function at the first affiliated hospital of jiaotong university from january 2018 to january 2022. exclusion criteria: * myocardial infarction complicated by cardiac rupture. * significant pre-existing heart failure. * other comorbidities such as malignancy that may significantly affect prognosis. * incomplete clinical data.

Keywords: acute myocardial infarction pulmonary hypertension